This brand name is authorized in Nigeria
The drug EXOSEA COD LIVER OIL contains a combination of these active pharmaceutical ingredients (APIs):
1
Vitamin A
UNII G2SH0XKK91 - RETINOL
|
Vitamin A plays an important role in the visual process. It is isomerised to the 11-cis isomer and subsequently bound to the opsin to form the photoreceptor for vision under subdued light. Vitamin A also participates in the formation and maintenance of the integrity of epithelial tissues and mucous membranes. |
2
Vitamin D3
UNII 1C6V77QF41 - CHOLECALCIFEROL
|
In its biologically active form vitamin D3 stimulates intestinal calcium absorption, incorporation of calcium into the osteoid, and release of calcium from bone tissue. In the small intestine it promotes rapid and delayed calcium uptake. The passive and active transport of phosphate is also stimulated. |
3
Vitamin E
UNII H4N855PNZ1 - .ALPHA.-TOCOPHEROL
|
Vitamin E is known to exert an important physiological function as an antioxidant for fats, with a sparing action on vitamin A, carotenoids and on unsaturated fatty acids. Other work has demonstrated that vitamin E is connected with the maintenance of certain factors essential for the normal metabolic cycle. |
4
Omega-3 fatty acids
UNII 71M78END5S - OMEGA-3 FATTY ACIDS
|
|
5
Docosahexaenoic acid
UNII ZAD9OKH9JC - DOCONEXENT
|
Docosahexaenoic acid (DHA) is an omega-3 fatty acid that is a primary structural component of the human brain, cerebral cortex, skin, and retina. It can be synthesized from alpha-linolenic acid or obtained directly from maternal milk (breast milk), fish oil, or algae oil. |
6
Eicosapentaenoic acid
UNII AAN7QOV9EA - ICOSAPENT
|
Icosapent ethyl is a stable ethyl ester of the omega-3 fatty acid, eicosapentaenoic acid (EPA). The mechanisms of action contributing to reduction of cardiovascular events with icosapent ethyl are not completely understood. The mechanisms are likely multi-factorial including improved lipoprotein profile with reduction of triglyceride-rich lipoproteins, anti-inflammatory, and antioxidant effects, reduction of macrophage accumulation, improved endothelial function, increased fibrous cap thickness/stability, and antiplatelet effects. Each of these mechanisms can beneficially alter the development, progression, and stabilisation of atherosclerotic plaque, as well as the implications of plaque rupture, and preclinical and clinical studies support such benefits with EPA. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
A11CB | Vitamin A and D in combination | A Alimentary tract and metabolism → A11 Vitamins → A11C Vitamin A and D, incl. combinations of the two |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: NG | Registered Drug Product Database | Identifier(s): A11-100625 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.